Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2024

Open Access 01-12-2024 | Multiple Sclerosis | Review

The role of CD56bright NK cells in neurodegenerative disorders

Authors: Carla Rodriguez-Mogeda, Chaja M. J. van Ansenwoude, Lennart van der Molen, Eva M. M. Strijbis, Reina E. Mebius, Helga E. de Vries

Published in: Journal of Neuroinflammation | Issue 1/2024

Login to get access

Abstract

Emerging evidence suggests a potential role for natural killer (NK) cells in neurodegenerative diseases, such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. However, the precise function of NK cells in these diseases remains ambiguous. The existence of two NK cell subsets, CD56bright and CD56dim NK cells, complicates the understanding of the contribution of NK cells in neurodegeneration as their functions within the context of neurodegenerative diseases may differ significantly. CD56bright NK cells are potent cytokine secretors and are considered more immunoregulatory and less terminally differentiated than their mostly cytotoxic CD56dim counterparts. Hence, this review focusses on NK cells, specifically on CD56bright NK cells, and their role in neurodegenerative diseases. Moreover, it explores the mechanisms underlying their ability to enter the central nervous system. By consolidating current knowledge, we aim to provide a comprehensive overview on the role of CD56bright NK cells in neurodegenerative diseases. Elucidating their impact on neurodegeneration may have implications for future therapeutic interventions, potentially ameliorating disease pathogenesis.
Literature
1.
Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells: 10 years on. Cell. 2018;174(5):1054–66.PubMedCrossRef
2.
Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells–a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13(2):145–9.PubMedCrossRef
3.
Dogra P, Rancan C, Ma W, Toth M, Senda T, Carpenter DJ, et al. Tissue determinants of human NK cell development, function, and residence. Cell. 2020;180(4):749–63.PubMedPubMedCentralCrossRef
4.
Rodríguez-Lorenzo S, van Olst L, Rodriguez-Mogeda C, Kamermans A, van der Pol SMA, Rodríguez E, et al. Single-cell profiling reveals periventricular CD56bright NK cell accumulation in multiple sclerosis. Elife. 2022;11:e73849.PubMedPubMedCentralCrossRef
5.
Jiang W, Chai NR, Maric D, Bielekova B. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol. 2011;187(2):781–90.PubMedCrossRef
6.
Solerte SB, Cravello L, Ferrari E, Fioravanti M. Overproduction of IFN-γ and TNF-α from natural killer (NK) cells is associated with abnormal NK reactivity and cognitive derangement in Alzheimer’s disease. Ann N Y Acad Sci. 2000;917(1):331–40.PubMedCrossRefADS
7.
Qi C, Liu F, Zhang W, Han Y, Zhang N, Liu Q, Li H. Alzheimer’s disease alters the transcriptomic profile of natural killer cells at single-cell resolution. Fronti Immunol. 2022;13.
8.
Melsen JE, Lugthart G, Lankester AC, Schilham MW. Human circulating and tissue-resident CD56(bright) natural killer cell populations. Front Immunol. 2016;7:262.PubMedPubMedCentralCrossRef
9.
Huang Y, Mao K, Germain RN. Thinking differently about ILCs-Not just tissue resident and not just the same as CD4(+) T-cell effectors. Immunol Rev. 2018;286(1):160–71.PubMedPubMedCentralCrossRef
10.
Lim AI, Li Y, Lopez-Lastra S, Stadhouders R, Paul F, Casrouge A, et al. Systemic human ILC precursors provide a substrate for tissue ILC differentiation. Cell. 2017;168(6):1086–100.PubMedCrossRef
11.
Mjosberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol. 2011;12(11):1055–62.PubMedCrossRef
12.
13.
Aglas-Leitner F, Juillard P, Juillard A, Byrne SN, Hawke S, Grau GE, Marsh-Wakefield F. Circulating CCR6(+)ILC proportions are lower in multiple sclerosis patients. Clin Transl Immunol. 2022;11(12): e1426.CrossRef
14.
Aglas-Leitner FT, Juillard P, Juillard A, Byrne SN, Hawke S, Grau GE, Marsh-Wakefield F. Mass cytometry reveals cladribine-induced resets among innate lymphoid cells in multiple sclerosis. Sci Rep. 2022;12(1):20411.PubMedPubMedCentralCrossRefADS
15.
16.
Mebius RE, Rennert P, Weissman IL. Developing lymph nodes collect CD4+CD3- LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity. 1997;7:493–504.PubMedCrossRef
17.
Veiga-Fernandes H, Coles MC, Foster KE, Patel A, Williams A, Natarajan D, et al. Tyrosine kinase receptor RET is a key regulator of Peyer’s patch organogenesis. Nature. 2007;446(7135):547–51.PubMedCrossRefADS
18.
19.
Grasso C, Pierie C, Mebius RE, van Baarsen LGM. Lymph node stromal cells: subsets and functions in health and disease. Trends Immunol. 2021;42(10):920–36.PubMedCrossRef
20.
Zhang J, Marotel M, Fauteux-Daniel S, Mathieu AL, Viel S, Marcais A, Walzer T. T-bet and Eomes govern differentiation and function of mouse and human NK cells and ILC1. Eur J Immunol. 2018;48(5):738–50.PubMedCrossRef
21.
Trabanelli S, Gomez-Cadena A, Salome B, Michaud K, Mavilio D, Landis BN, et al. Human innate lymphoid cells (ILCs): Toward a uniform immune-phenotyping. Cytometry B Clin Cytom. 2018;94(3):392–9.PubMedCrossRef
22.
Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med. 2012;209(13):2351–65.PubMedPubMedCentralCrossRef
23.
Oka N, Markova T, Tsuzuki K, Li W, El-Darawish Y, Pencheva-Demireva M, et al. IL-12 regulates the expansion, phenotype, and function of murine NK cells activated by IL-15 and IL-18. Cancer Immunol Immunother. 2020;69(9):1699–712.PubMedCrossRef
24.
Martin JF, Perry JSA, Jakhete NR, Wang X, Bielekova B. An IL-2 paradox: blocking CD25 on T cells induces IL-2–driven activation of CD56bright NK cells. J Immunol. 2010;185(2):1311–20.PubMedCrossRef
25.
Kellner C, Gramatzki M, Peipp M. Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype. Oncoimmunology. 2013;2(6): e24481.PubMedPubMedCentralCrossRef
26.
27.
Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L, et al. Identification and molecular characterization of Nkp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med. 1999;190(10):1505–16.PubMedPubMedCentralCrossRef
28.
Raulet DH. Missing self recognition and self tolerance of natural killer (NK) cells. Semin Immunol. 2006;18(3):145–50.PubMedCrossRef
29.
Moretta L, Moretta A. Killer immunoglobulin-like receptors. Curr Opin Immunol. 2004;16(5):626–33.PubMedCrossRef
30.
Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol. 2019;105(6):1319–29.PubMedCrossRef
31.
Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–10.PubMedCrossRef
32.
Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood. 2010;115(11):2167–76.PubMedPubMedCentralCrossRef
33.
34.
Tosello-Trampont A, Surette FA, Ewald SE, Hahn YS. Immunoregulatory role of NK cells in tissue inflammation and regeneration. Front Immunol. 2017;8:301.PubMedPubMedCentralCrossRef
35.
36.
37.
Seo S, Mace EM. Diversity of human NK cell developmental pathways defined by single-cell analyses. Curr Opin Immunol. 2022;74:106–11.PubMedCrossRef
38.
Romagnani C, Juelke K, Falco M, Morandi B, D’Agostino A, Costa R, et al. CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol. 2007;178(8):4947–55.PubMedCrossRef
39.
Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol. 2007;179(1):89–94.PubMedCrossRef
40.
Beziat V, Duffy D, Quoc SN, Le Garff-Tavernier M, Decocq J, Combadiere B, et al. CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation. J Immunol. 2011;186(12):6753–61.PubMedCrossRef
41.
Vujanovic L, Chuckran C, Lin Y, Ding F, Sander CA, Santos PM, et al. CD56(dim) CD16(-) natural killer cell profiling in melanoma patients receiving a cancer vaccine and interferon-alpha. Front Immunol. 2019;10:14.PubMedPubMedCentralCrossRef
42.
Muller-Durovic B, Grahlert J, Devine OP, Akbar AN, Hess C. CD56-negative NK cells with impaired effector function expand in CMV and EBV co-infected healthy donors with age. Aging (Albany NY). 2019;11(2):724–40.PubMedCrossRef
43.
Gonzalez VD, Falconer K, Bjorkstrom NK, Blom KG, Weiland O, Ljunggren HG, et al. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment. J Immunol. 2009;183(10):6612–8.PubMedCrossRef
44.
45.
Collins PL, Cella M, Porter SI, Li S, Gurewitz GL, Hong HS, et al. Gene regulatory programs conferring phenotypic identities to human NK cells. Cell. 2019;176(1–2):348–60.PubMedCrossRef
46.
Bernardini G, Antonangeli F, Bonanni V, Santoni A. Dysregulation of chemokine/chemokine receptor axes and NK cell tissue localization during diseases. Front Immunol. 2016;7:402.PubMedPubMedCentralCrossRef
47.
Castriconi R, Carrega P, Dondero A, Bellora F, Casu B, Regis S, et al. Molecular mechanisms directing migration and retention of natural killer cells in human tissues. Front Immunol. 2018;9:2324.PubMedPubMedCentralCrossRef
48.
Lin SJ, Kuo ML, Hsiao HS, Lee PT, Lee WI, Chen JY, Huang JL. Cytotoxic function and cytokine production of natural killer cells and natural killer T-like cells in systemic lupus erythematosis regulation with interleukin-15. Mediators Inflamm. 2019;2019:4236562.PubMedPubMedCentralCrossRef
49.
Plantone D, Marti A, Frisullo G, Iorio R, Damato V, Nociti V, et al. Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis. J Neuroimmunol. 2013;265(1):124–7.PubMedCrossRef
50.
51.
Bhatnagar N, Ahmad F, Hong HS, Eberhard J, Lu IN, Ballmaier M, et al. FcgammaRIII (CD16)-mediated ADCC by NK cells is regulated by monocytes and FcgammaRII (CD32). Eur J Immunol. 2014;44(11):3368–79.PubMedCrossRef
52.
Nielsen N, Odum N, Urso B, Lanier LL, Spee P. Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A. PLoS ONE. 2012;7(2): e31959.PubMedPubMedCentralCrossRefADS
53.
Laroni A, Armentani E, Kerlero de Rosbo N, Ivaldi F, Marcenaro E, Sivori S, et al. Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis. J Autoimmun. 2016;72:8–18.PubMedCrossRef
54.
Bratke K, Kuepper M, Bade B, Virchow JC Jr, Luttmann W. Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood. Eur J Immunol. 2005;35(9):2608–16.PubMedCrossRef
55.
Wendt K, Wilk E, Buyny S, Buer J, Schmidt RE, Jacobs R. Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells. J Leukoc Biol. 2006;80(6):1529–41.PubMedCrossRef
56.
Boivin WA, Cooper DM, Hiebert PR, Granville DJ. Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab Invest. 2009;89(11):1195–220.PubMedPubMedCentralCrossRef
57.
58.
Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. 2013;31:227–58.PubMedCrossRef
59.
Michel T, Poli A, Cuapio A, Briquemont B, Iserentant G, Ollert M, Zimmer J. Human CD56bright NK cells: an update. J Immunol. 2016;196(7):2923–31.PubMedCrossRef
60.
Del Zotto G, Antonini F, Pesce S, Moretta F, Moretta L, Marcenaro E. Comprehensive phenotyping of human PB NK cells by flow cytometry. Cytometry A. 2020;97(9):891–9.PubMedCrossRef
61.
Gross CC, Schulte-Mecklenbeck A, Runzi A, Kuhlmann T, Posevitz-Fejfar A, Schwab N, et al. Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proc Natl Acad Sci U S A. 2016;113(21):E2973–82.PubMedPubMedCentralCrossRef
62.
63.
Ferlazzo G, Moretta L. Dendritic cell editing by natural killer cells. Crit Rev Oncog. 2014;19(1–2):67–75.PubMedCrossRef
64.
Zuo W, Zhao X. Natural killer cells play an important role in virus infection control: antiviral mechanism, subset expansion and clinical application. Clin Immunol. 2021;227: 108727.PubMedPubMedCentralCrossRef
65.
Luetke-Eversloh M, Cicek BB, Siracusa F, Thom JT, Hamann A, Frischbutter S, et al. NK cells gain higher IFN-gamma competence during terminal differentiation. Eur J Immunol. 2014;44(7):2074–84.PubMedCrossRef
66.
Bjorkstrom NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood. 2010;116(19):3853–64.PubMedCrossRef
67.
Brauning A, Rae M, Zhu G, Fulton E, Admasu TD, Stolzing A, Sharma A. Aging of the immune system: focus on natural killer cells phenotype and functions. Cells. 2022;11(6):1017.PubMedPubMedCentralCrossRef
68.
Solana R, Campos C, Pera A, Tarazona R. Shaping of NK cell subsets by aging. Curr Opin Immunol. 2014;29:56–61.PubMedCrossRef
69.
Hayhoe RP, Henson SM, Akbar AN, Palmer DB. Variation of human natural killer cell phenotypes with age: identification of a unique KLRG1-negative subset. Hum Immunol. 2010;71(7):676–81.PubMedCrossRef
70.
Almeida-Oliveira A, Smith-Carvalho M, Porto LC, Cardoso-Oliveira J, Ribeiro AS, Falcão RR, et al. Age-related changes in natural killer cell receptors from childhood through old age. Hum Immunol. 2011;72:319–29.PubMedCrossRef
71.
Campos C, Lopez N, Pera A, Gordillo JJ, Hassouneh F, Tarazona R, Solana R. Expression of NKp30, NKp46 and DNAM-1 activating receptors on resting and IL-2 activated NK cells from healthy donors according to CMV-serostatus and age. Biogerontology. 2015;16(5):671–83.PubMedCrossRef
72.
Sanchez-Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S, Solana R, Tarazona R. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol. 2012;90(1):109–15.PubMedCrossRef
73.
Silva A, Andrews DM, Brooks AG, Smyth MJ, Hayakawa Y. Application of CD27 as a marker for distinguishing human NK cell subsets. Int Immunol. 2008;20(4):625–30.PubMedCrossRef
74.
Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol. 2006;176(3):1517–24.PubMedCrossRef
75.
Crinier A, Milpied P, Escaliere B, Piperoglou C, Galluso J, Balsamo A, et al. High-dimensional single-cell analysis identifies organ-specific signatures and conserved NK cell subsets in humans and mice. Immunity. 2018;49(5):971–86.PubMedPubMedCentralCrossRef
76.
Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T. Maturation of mouse NK cells is a 4-stage developmental program. Blood. 2009;113(22):5488–96.PubMedCrossRef
77.
78.
Vossen MT, Matmati M, Hertoghs KM, Baars PA, Gent MR, Leclercq G, et al. CD27 defines phenotypically and functionally different human NK cell subsets. J Immunol. 2008;180(6):3739–45.PubMedCrossRef
79.
Fu B, Wang F, Sun R, Ling B, Tian Z, Wei H. CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells. Immunology. 2011;133(3):350–9.PubMedPubMedCentralCrossRef
80.
Kameritsch P, Renkawitz J. Principles of leukocyte migration strategies. Trends Cell Biol. 2020;30(10):818–32.PubMedCrossRef
81.
van Olst L, Coenen L, Nieuwland JM, Rodriguez-Mogeda C, de Wit NM, Kamermans A, et al. Crossing borders in Alzheimer’s disease: a T cell’s perspective. Adv Drug Deliv Rev. 2022;188: 114398.PubMedCrossRef
82.
83.
Hermans D, Rodriguez-Mogeda C, Kemps H, Bronckaers A, de Vries HE, Broux B. Nectins and Nectin-like molecules drive vascular development and barrier function. Angiogenesis. 2023;26(3):349–62.PubMedCrossRef
84.
Carrega P, Bonaccorsi I, Di Carlo E, Morandi B, Paul P, Rizzello V, et al. CD56(bright)perforin(low) noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph. J Immunol. 2014;192(8):3805–15.PubMedCrossRef
85.
Schwane V, Huynh-Tran VH, Vollmers S, Yakup VM, Sauter J, Schmidt AH, et al. Distinct signatures in the receptor repertoire discriminate CD56bright and CD56dim natural killer cells. Front Immunol. 2020;11: 568927.PubMedPubMedCentralCrossRef
86.
Mailliard RB, Alber SM, Shen H, Watkins SC, Kirkwood JM, Herberman RB, Kalinski P. IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med. 2005;202(7):941–53.PubMedPubMedCentralCrossRef
87.
Levy ER, Clara JA, Reger RN, Allan DSJ, Childs RW. RNA-Seq analysis reveals CCR5 as a key target for CRISPR gene editing to regulate in vivo NK cell trafficking. Cancers (Basel). 2021;13(4):872.PubMedPubMedCentralCrossRef
88.
Lin SJ, Chen JY, Kuo ML, Hsiao HS, Lee PT, Huang JL. Effect of Interleukin-15 on CD11b, CD54, and CD62L expression on natural killer cell and natural killer T-like cells in systemic lupus erythematosus. Mediators Inflamm. 2016;2016:9675861.PubMedPubMedCentralCrossRef
89.
90.
Stamatovic SM, Keep RF, Andjelkovic AV. Brain endothelial cell-cell junctions: how to “open” the blood brain barrier. Curr Neuropharmacol. 2008;6(3):179–92.PubMedPubMedCentralCrossRef
91.
92.
Haruwaka K, Ikegami A, Tachibana Y, Ohno N, Konishi H, Hashimoto A, et al. Dual microglia effects on blood brain barrier permeability induced by systemic inflammation. Nat Commun. 2019;10(1):5816.PubMedPubMedCentralCrossRefADS
93.
Chakraborty A, de Wit NM, van der Flier WM, de Vries HE. The blood brain barrier in Alzheimer’s disease. Vascul Pharmacol. 2017;89:12–8.PubMedCrossRef
94.
Solar P, Zamani A, Kubickova L, Dubovy P, Joukal M. Choroid plexus and the blood-cerebrospinal fluid barrier in disease. Fluids Barriers CNS. 2020;17(1):35.PubMedPubMedCentralCrossRef
95.
96.
Rodriguez-Mogeda C, Rodriguez-Lorenzo S, Attia J, van Horssen J, Witte ME, de Vries HE. Breaching brain barriers: B cell migration in multiple sclerosis. Biomolecules. 2022;12(6):800.PubMedPubMedCentralCrossRef
97.
Hansen DS, Bernard NJ, Nie CQ, Schofield L. NK cells stimulate recruitment of CXCR3+ T cells to the brain during Plasmodium berghei-mediated cerebral malaria. J Immunol. 2007;178(9):5779–88.PubMedCrossRef
98.
Poli A, Kmiecik J, Domingues O, Hentges F, Blery M, Chekenya M, et al. NK cells in central nervous system disorders. J Immunol. 2013;190(11):5355–62.PubMedCrossRef
99.
Herich S, Schneider-Hohendorf T, Rohlmann A, Khaleghi Ghadiri M, Schulte-Mecklenbeck A, Zondler L, et al. Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. Brain. 2019;142(11):3411–27.PubMedCrossRef
100.
Lin YC, Winokur P, Blake A, Wu T, Romm E, Bielekova B. Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis. Ann Clin Transl Neurol. 2015;2(5):445–55.PubMedPubMedCentralCrossRef
101.
Busse S, Hoffmann J, Michler E, Hartig R, Frodl T, Busse M. Dementia-associated changes of immune cell composition within the cerebrospinal fluid. Brain Behav Immun Health. 2021;14: 100218.PubMedPubMedCentralCrossRef
102.
Ho EL, Ronquillo R, Altmeppen H, Spudich SS, Price RW, Sinclair E. Cellular composition of cerebrospinal fluid in HIV-1 infected and uninfected subjects. PLoS ONE. 2013;8(6): e66188.PubMedPubMedCentralCrossRefADS
103.
Han S, Lin YC, Wu T, Salgado AD, Mexhitaj I, Wuest SC, et al. Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases. J Immunol. 2014;192(6):2551–63.PubMedCrossRef
104.
Van Hove H, Martens L, Scheyltjens I, De Vlaminck K, Pombo Antunes AR, De Prijck S, et al. A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nat Neurosci. 2019;22(6):1021–35.PubMedCrossRef
105.
Hobson R, Levy SHS, Flaherty D, Xiao H, Ciener B, Reddy H, et al. Clonal CD8 T cells in the leptomeninges are locally controlled and influence microglia in human neurodegeneration. bioRxiv. 2023:2023.07.13.548931.
106.
Lopes Pinheiro MA, Kooij G, Mizee MR, Kamermans A, Enzmann G, Lyck R, et al. Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke. Biochim Biophys Acta. 2016;1862(3):461–71.PubMedCrossRef
107.
Kooij G, Kopplin K, Blasig R, Stuiver M, Koning N, Goverse G, et al. Disturbed function of the blood-cerebrospinal fluid barrier aggravates neuro-inflammation. Acta Neuropathol. 2014;128(2):267–77.PubMedCrossRef
108.
Coisne C, Engelhardt B. Tight junctions in brain barriers during central nervous system inflammation. Antioxid Redox Signal. 2011;15(5):1285–303.PubMedCrossRef
109.
Demeestere D, Libert C, Vandenbroucke RE. Clinical implications of leukocyte infiltration at the choroid plexus in (neuro)inflammatory disorders. Drug Discov Today. 2015;20(8):928–41.PubMedCrossRef
110.
Absinta M, Cortese IC, Vuolo L, Nair G, de Alwis MP, Ohayon J, et al. Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. Neurology. 2017;88(15):1439–44.PubMedPubMedCentralCrossRef
111.
Absinta M, Reich DS. Imaging of meningeal inflammation should become part of the routine MRI protocol—yes. Mult Scler. 2019;25(3):330–1.PubMedCrossRef
112.
113.
114.
115.
Chu F, Shi M, Zheng C, Shen D, Zhu J, Zheng X, Cui L. The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neuroimmunol. 2018;318:1–7.PubMedCrossRef
116.
Van Kaer L, Postoak JL, Wang C, Yang G, Wu L. Innate, innate-like and adaptive lymphocytes in the pathogenesis of MS and EAE. Cell Mol Immunol. 2019;16(6):531–9.PubMedPubMedCentralCrossRef
117.
Zeng B, Shi S, Ashworth G, Dong C, Liu J, Xing F. ILC3 function as a double-edged sword in inflammatory bowel diseases. Cell Death Dis. 2019;10(4):315.PubMedPubMedCentralCrossRef
118.
Xiong T, Turner JE. Innate lymphoid cells in autoimmunity and chronic inflammatory diseases. Semin Immunopathol. 2018;40(4):393–406.PubMedCrossRef
119.
Constantinescu CS, Farooqi N, O’Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 2011;164(4):1079–106.PubMedPubMedCentralCrossRef
120.
Gao M, Yang Y, Li D, Ming B, Chen H, Sun Y, et al. CD27 natural killer cell subsets play different roles during the pre-onset stage of experimental autoimmune encephalomyelitis. Innate Immun. 2016;22(6):395–404.PubMedCrossRef
121.
122.
Mimpen M, Smolders J, Hupperts R, Damoiseaux J. Natural killer cells in multiple sclerosis: a review. Immunol Lett. 2020;222:1–11.PubMedCrossRef
123.
Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A. 2006;103(15):5941–6.PubMedPubMedCentralCrossRefADS
124.
Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010;9(4):381–90.PubMedCrossRef
125.
Arasanz H, Gato-Cañas M, Zuazo M, Ibañez-Vea M, Breckpot K, Kochan G, Escors D. PD1 signal transduction pathways in T cells. Oncotarget. 2017;8(31):51936–45.PubMedPubMedCentralCrossRef
126.
Airas L, Saraste M, Rinta S, Elovaara I, Huang YH, Wiendl H. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol. 2008;151(2):235–43.PubMedPubMedCentralCrossRef
127.
Durrenberger PF, Webb LV, Sim MJ, Nicholas RS, Altmann DM, Boyton RJ. Increased HLA-E expression in white matter lesions in multiple sclerosis. Immunology. 2012;137(4):317–25.PubMedPubMedCentralCrossRef
128.
Morandi F, Venturi C, Rizzo R, Castellazzi M, Baldi E, Caniatti ML, et al. Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation. J Neuroimmune Pharmacol. 2013;8(4):944–55.PubMedCrossRef
129.
De Maria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A. 2011;108(2):728–32.PubMedCrossRefADS
130.
Steinman L. Blockade of gamma interferon might be beneficial in MS. Mult Scler J. 2001;7(5):275–6.CrossRef
131.
Lin W, Kemper A, Dupree JL, Harding HP, Ron D, Popko B. Interferon-γ inhibits central nervous system remyelination through a process modulated by endoplasmic reticulum stress. Brain. 2006;129(5):1306–18.PubMedCrossRef
132.
Tahrali I, Kucuksezer UC, Altintas A, Uygunoglu U, Akdeniz N, Aktas-Cetin E, Deniz G. Dysfunction of CD3−CD16+CD56dim and CD3−CD16−CD56bright NK cell subsets in RR-MS patients. Clin Immunol. 2018;193:88–97.PubMedCrossRef
133.
Lünemann A, Tackenberg B, DeAngelis T, Barreira da Silva R, Messmer B, Vanoaica LD, et al. Impaired IFN-γ production and proliferation of NK cells in multiple sclerosis. Int Immunol. 2011;23(2):139–48.PubMedPubMedCentralCrossRef
134.
Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med. 1997;186(10):1677–87.PubMedPubMedCentralCrossRef
135.
Hao J, Liu R, Piao W, Zhou Q, Vollmer TL, Campagnolo DI, et al. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med. 2010;207(9):1907–21.PubMedPubMedCentralCrossRef
136.
Romero-Suarez S, Del Rio SA, Bueno RJ, Brunotte-Strecker D, Stehle C, Figueiredo CA, et al. The central nervous system contains ILC1s that differ from NK cells in the response to inflammation. Front Immunol. 2019;10:2337.PubMedPubMedCentralCrossRef
137.
Winkler-Pickett R, Young HA, Cherry JM, Diehl J, Wine J, Back T, et al. In vivo regulation of experimental autoimmune encephalomyelitis by NK cells: alteration of primary adaptive responses12. J Immunol. 2008;180(7):4495–506.PubMedCrossRef
138.
Sung CC, Horng JH, Siao SH, Chyuan IT, Tsai HF, Chen PJ, Hsu PN. Asialo GM1-positive liver-resident CD8 T cells that express CD44 and LFA-1 are essential for immune clearance of hepatitis B virus. Cell Mol Immunol. 2021;18(7):1772–82.PubMedCrossRef
139.
Huang D, Shi FD, Jung S, Pien GC, Wang J, Salazar-Mather TP, et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. Faseb J. 2006;20(7):896–905.PubMedCrossRef
140.
Hertwig L, Hamann I, Romero-Suarez S, Millward JM, Pietrek R, Chanvillard C, et al. CX3CR1-dependent recruitment of mature NK cells into the central nervous system contributes to control autoimmune neuroinflammation. Eur J Immunol. 2016;46(8):1984–96.PubMedPubMedCentralCrossRef
141.
Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, Hodge MR, et al. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol. 2001;166(11):6477–82.PubMedCrossRef
142.
Kawashima K, Fujii T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci. 2003;74(6):675–96.PubMedCrossRef
143.
Jiang W, Li D, Han R, Zhang C, Jin W-N, Wood K, et al. Acetylcholine-producing NK cells attenuate CNS inflammation via modulation of infiltrating monocytes/macrophages. Proc Natl Acad Sci. 2017;114(30):E6202–11.PubMedPubMedCentralCrossRef
144.
Liu Q, Sanai N, Jin WN, La Cava A, Van Kaer L, Shi FD. Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. Nat Neurosci. 2016;19(2):243–52.PubMedPubMedCentralCrossRef
145.
146.
Lorefice L, Fenu G, Frau J, Coghe G, Marrosu MG. Monoclonal antibodies: a target therapy for multiple sclerosis. Inflamm Allergy Drug Targets. 2014;13(2):134–43.PubMedCrossRef
147.
Hollen CW, Paz Soldán MM, Rinker JR 2nd, Spain RI. The future of progressive multiple sclerosis therapies. Fed Pract. 2020;37(Suppl 1):S43–9.PubMedPubMedCentral
148.
149.
Waldmann TA, Goldman CK, Bongiovanni KF, Sharrow SO, Davey MP, Cease KB, et al. Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood. 1988;72(5):1805–16.PubMedCrossRef
150.
Perry JS, Han S, Xu Q, Herman ML, Kennedy LB, Csako G, Bielekova B. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med. 2012;4(145):145ra06.CrossRef
151.
Wuest SC, Edwan JH, Martin JF, Han S, Perry JS, Cartagena CM, et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med. 2011;17(5):604–9.PubMedPubMedCentralCrossRef
152.
Rommer PS, Berger K, Ellenberger D, Fneish F, Simbrich A, Stahmann A, Zettl UK. Management of MS patients treated with daclizumab—a case series of 267 patients. Front Neurol. 2020;11:996.PubMedPubMedCentralCrossRef
153.
Giovannoni G, Kappos L, Gold R, Khatri BO, Selmaj K, Umans K, et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: an integrated analysis of clinical studies. Mult Scler Relat Disord. 2016;9:36–46.PubMedCrossRef
154.
Stork L, Brück W, von Gottberg P, Pulkowski U, Kirsten F, Glatzel M, et al. Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis. Mult Scler. 2019;25(12):1618–32.PubMedCrossRef
155.
Faissner S, Gold R. Efficacy and safety of the newer multiple sclerosis drugs approved since 2010. CNS Drugs. 2018;32(3):269–87.PubMedCrossRef
156.
Gold R, Radue E-W, Giovannoni G, Selmaj K, Havrdova EK, Montalban X, et al. Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. J Neurol. 2020;267(10):2851–64.PubMedPubMedCentralCrossRef
157.
The L. End of the road for daclizumab in multiple sclerosis. Lancet. 2018;391(10125):1000.CrossRef
158.
Stettner M, Gross CC, Mausberg AK, Pul R, Junker A, Baba HA, et al. A fatal case of daclizumab-induced liver failure in a patient with MS. Neurol Neuroimmunol Neuroinflamm. 2019;6(2): e539.PubMedPubMedCentralCrossRef
159.
Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology. 2005;64(8):1336–42.PubMedCrossRef
160.
Mellergård J, Edström M, Jenmalm MC, Dahle C, Vrethem M, Ernerudh J. Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients. PLoS ONE. 2013;8(12): e81685.PubMedPubMedCentralCrossRefADS
161.
Gan Y, Liu R, Wu W, Bomprezzi R, Shi FD. Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2012;247(1–2):9–15.PubMedPubMedCentralCrossRef
162.
Yong VW. Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Neurology. 2002;59(6):802–8.PubMedCrossRef
163.
Saraste M, Irjala H, Airas L. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci. 2007;28(3):121–6.PubMedCrossRef
164.
Vandenbark AA, Huan J, Agotsch M, La Tocha D, Goelz S, Offner H, et al. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol. 2009;215(1):125–8.PubMedCrossRef
165.
Martínez-Rodríguez JE, López-Botet M, Munteis E, Rio J, Roquer J, Montalban X, Comabella M. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clin Immunol. 2011;141(3):348–56.PubMedCrossRef
166.
Schrempf W, Ziemssen T. Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev. 2007;6(7):469–75.PubMedCrossRef
167.
Al-Falahi Y, Sand KL, Knudsen E, Damaj BB, Rolin J, Maghazachi AA. Splenic natural killer cell activity in two models of experimental neurodegenerative diseases. J Cell Mol Med. 2009;13(8b):2693–703.PubMedCrossRef
168.
Sand KL, Knudsen E, Rolin J, Al-Falahi Y, Maghazachi AA. Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate. Cell Mol Life Sci. 2009;66(8):1446–56.PubMedCrossRef
169.
Høglund RA, Holmøy T, Harbo HF, Maghazachi AA. A one year follow-up study of natural killer and dendritic cells activities in multiple sclerosis patients receiving glatiramer acetate (GA). PLoS ONE. 2013;8(4): e62237.PubMedPubMedCentralCrossRefADS
170.
Spadaro M, Montarolo F, Perga S, Martire S, Brescia F, Malucchi S, Bertolotto A. Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10 years in responder multiple sclerosis patients. Clin Immunol. 2017;181:83–8.PubMedCrossRef
171.
Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci. 2013;328(1–2):9–18.PubMedPubMedCentralCrossRef
172.
Walzer T, Chiossone L, Chaix J, Calver A, Carozzo C, Garrigue-Antar L, et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol. 2007;8(12):1337–44.PubMedCrossRef
173.
Johnson TA, Evans BL, Durafourt BA, Blain M, Lapierre Y, Bar-Or A, Antel JP. Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients. J Immunol. 2011;187(1):570–9.PubMedCrossRef
174.
Acar NP, Tuncer A, Ozkazanc D, Ozbay FG, Karaosmanoglu B, Goksen S, et al. An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-β1 and fingolimod therapy. J Neuroimmunol. 2020;347: 577353.PubMedCrossRef
175.
176.
Smith MD, Calabresi PA, Bhargava P. Dimethyl fumarate treatment alters NK cell function in multiple sclerosis. Eur J Immunol. 2018;48(2):380–3.PubMedCrossRef
177.
Medina S, Villarrubia N, Sainz de la Maza S, Lifante J, Costa-Frossard L, Roldán E, et al. Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile. Mult Scler J. 2018;24(10):1317–27.CrossRef
178.
Fernández-Velasco JI, Kuhle J, Monreal E, Meca-Lallana V, Meca-Lallana J, Izquierdo G, et al. Effect of ocrelizumab in blood leukocytes of patients with primary progressive MS. Neurol Neuroimmunol Neuroinflamm. 2021;8(2).
179.
Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34(1):28–35.PubMedCrossRef
180.
Berente DB, Kamondi A, Horvath AA. The assessment of visuospatial skills and verbal fluency in the diagnosis of Alzheimer’s disease. Front Aging Neurosci. 2022;13.
181.
182.
van der Lee SJ, Wolters FJ, Ikram MK, Hofman A, Ikram MA, Amin N, van Duijn CM. The effect of APOE and other common genetic variants on the onset of Alzheimer’s disease and dementia: a community-based cohort study. Lancet Neurol. 2018;17(5):434–44.PubMedCrossRef
183.
Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, et al. APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline. Nature. 2020;581(7806):71–6.PubMedPubMedCentralCrossRefADS
184.
Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414–30.PubMedPubMedCentralCrossRef
185.
Gate D, Saligrama N, Leventhal O, Yang AC, Unger MS, Middeldorp J, et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease. Nature. 2020;577(7790):399–404.PubMedPubMedCentralCrossRefADS
186.
Thakur S, Dhapola R, Sarma P, Medhi B, Reddy DH. Neuroinflammation in Alzheimer’s disease: current progress in molecular signaling and therapeutics. Inflammation. 2023;46(1):1–17.PubMedCrossRef
187.
Drummond E, Wisniewski T. Alzheimer’s disease: experimental models and reality. Acta Neuropathol. 2017;133(2):155–75.PubMedCrossRef
188.
Lyons A, Murphy KJ, Clarke R, Lynch MA. Atorvastatin prevents age-related and amyloid-β-induced microglial activation by blocking interferon-γ release from natural killer cells in the brain. J Neuroinflammation. 2011;8(1):27.PubMedPubMedCentralCrossRef
189.
Zhang Y, Fung ITH, Sankar P, Chen X, Robison LS, Ye L, et al. Depletion of NK cells improves cognitive function in the Alzheimer disease mouse model. J Immunol. 2020;205(2):502–10.PubMedCrossRef
190.
Le Page A, Bourgade K, Lamoureux J, Frost E, Pawelec G, Larbi A, et al. NK cells are activated in amnestic mild cognitive Impairment but not in Mild Alzheimer’s disease patients. J Alzheimers Dis. 2015;46:93–107.PubMedCrossRef
191.
Richartz-Salzburger E, Batra A, Stransky E, Laske C, Köhler N, Bartels M, et al. Altered lymphocyte distribution in Alzheimer’s disease. J Psychiatr Res. 2007;41(1):174–8.PubMedCrossRef
192.
Udan ML, Ajit D, Crouse NR, Nichols MR. Toll-like receptors 2 and 4 mediate Abeta(1–42) activation of the innate immune response in a human monocytic cell line. J Neurochem. 2008;104(2):524–33.PubMedCrossRef
193.
Maté I, Cruces J, Giménez-Llort L, De la Fuente M. Function and redox state of peritoneal leukocytes as preclinical and prodromic markers in a longitudinal study of triple-transgenic mice for Alzheimer’s disease. J Alzheimers Dis. 2015;43:213–26.PubMedCrossRef
194.
Marsh SE, Abud EM, Lakatos A, Karimzadeh A, Yeung ST, Davtyan H, et al. The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function. Proc Natl Acad Sci. 2016;113(9):E1316–25.PubMedPubMedCentralCrossRef
195.
Mittal K, Eremenko E, Berner O, Elyahu Y, Strominger I, Apelblat D, et al. CD4 T cells induce a subset of MHCII-expressing microglia that attenuates alzheimer pathology. iScience. 2019;16:298–311.PubMedPubMedCentralCrossRefADS
196.
Girek M, Szymański P. Tacrine hybrids as multi-target-directed ligands in Alzheimer’s disease: influence of chemical structures on biological activities. Chem Pap. 2019;73(2):269–89.CrossRef
197.
Crismon ML. Tacrine: first drug approved for Alzheimer’s disease. Ann Pharmacother. 1994;28(6):744–51.PubMedCrossRef
198.
Krishnaraj R. Immunomodulation by 9-amino-1,2,3,4-tetrahydroacridine (THA): 1. Down-regulation of natural cell-mediated cytotoxicity in vitro. Immunopharmacology. 1991;22(2):69–76.PubMedCrossRef
199.
Torrandell-Haro G, Branigan GL, Vitali F, Geifman N, Zissimopoulos JM, Brinton RD. Statin therapy and risk of Alzheimer’s and age-related neurodegenerative diseases. Alzheimer’s Dement (N Y). 2020;6(1): e12108.CrossRef
200.
Zhang YY, Fan YC, Wang M, Wang D, Li XH. Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer’s disease. Clin Interv Aging. 2013;8:103–10.PubMedPubMedCentral
201.
Jeong S-M, Shin DW, Yoo TG, Cho MH, Jang W, Lee J, Kim S. Association between statin use and Alzheimer’s disease with dose response relationship. Sci Rep. 2021;11(1):15280.PubMedPubMedCentralCrossRef
202.
203.
Chua-Alcala VS, Chawla SP, Gordon EM, Kim TT, Sekhon S, Feske W, et al. Preliminary analysis of a phase I study of SNK01 (Autologous Non-genetically Modified Natural Killer Cells With Enhanced Cytotoxicity) monotherapy in patients with advanced solid tumors. J Clin Oncol. 2022;40(16_suppl):2644.CrossRef
204.
205.
White AJ, Wijeyekoon RS, Scott KM, Gunawardana NP, Hayat S, Solim IH, et al. The peripheral inflammatory response to alpha-synuclein and endotoxin in Parkinson’s disease. Front Neurol. 2018;9:946.PubMedPubMedCentralCrossRef
206.
Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435–50.PubMedCrossRef
207.
Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3(1):17013.PubMedCrossRef
208.
Ferguson LW, Rajput AH, Rajput A. Early-onset vs. late-onset Parkinson’s disease: a clinical-pathological study. Can J Neurol Sci. 2016;43(1):113–9.PubMedCrossRef
209.
210.
Williams GP, Schonhoff AM, Jurkuvenaite A, Gallups NJ, Standaert DG, Harms AS. CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson’s disease. Brain. 2021;144(7):2047–59.PubMedPubMedCentralCrossRef
211.
Konnova EA, Swanberg M. Animal Models of Parkinson’s Disease. In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects. Brisbane (AU): Codon Publications. Copyright: The Authors; 2018.
212.
Menees KB, Lee J-K. New insights and implications of natural killer cells in Parkinson’s disease. J Parkinson’s Dis. 2022;12:S83–92.CrossRef
213.
214.
Niwa F, Kuriyama N, Nakagawa M, Imanishi J. Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson’s disease. Geriatr Gerontol Int. 2012;12(1):102–7.PubMedCrossRef
215.
Sun C, Zhao Z, Yu W, Mo M, Song C, Si Y, Liu Y. Abnormal subpopulations of peripheral blood lymphocytes are involved in Parkinson’s disease. Ann Transl Med. 2019;7(22):637.PubMedPubMedCentralCrossRef
216.
Earls RH, Menees KB, Chung J, Gutekunst C-A, Lee HJ, Hazim MG, et al. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy. Proc Natl Acad Sci. 2020;117(3):1762–71.PubMedPubMedCentralCrossRefADS
217.
Chen L, Wang Y, Huang J, Hu B, Huang W. Identification of immune-related hub genes in Parkinson’s disease. Front Genet. 2022;13.
218.
Perner C, Perner F, Gaur N, Zimmermann S, Witte OW, Heidel FH, et al. Plasma VCAM1 levels correlate with disease severity in Parkinson’s disease. J Neuroinflammation. 2019;16(1):94.PubMedPubMedCentralCrossRef
219.
Mihara T, Nakashima M, Kuroiwa A, Akitake Y, Ono K, Hosokawa M, et al. Natural killer cells of Parkinson’s disease patients are set up for activation: a possible role for innate immunity in the pathogenesis of this disease. Parkinsonism Relat Disord. 2008;14(1):46–51.PubMedCrossRef
220.
221.
Gurturk Z, Tezcaner A, Dalgic AD, Korkmaz S, Keskin D. Maltodextrin modified liposomes for drug delivery through the blood–brain barrier. MedChemComm. 2017;8(6):1337–45.PubMedPubMedCentralCrossRef
222.
Stevens CH, Rowe D, Morel-Kopp M-C, Orr C, Russell T, Ranola M, et al. Reduced T helper and B lymphocytes in Parkinson’s disease. J Neuroimmunol. 2012;252(1):95–9.PubMedCrossRef
223.
Gangemi S, Basile G, Merendino RA, Epifanio A, Di Pasquale G, Ferlazzo B, et al. Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson’s disease. Mediators Inflamm. 2003;12(4):251–3.PubMedPubMedCentralCrossRef
224.
Mikulak J, Bozzo L, Roberto A, Pontarini E, Tentorio P, Hudspeth K, et al. Dopamine inhibits the effector functions of activated NK cells via the upregulation of the D5 receptor. J Immunol. 2014;193(6):2792–800.PubMedCrossRef
225.
226.
Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, Sobue G. Amyotrophic lateral sclerosis. The Lancet. 2022;400(10360):1363–80.CrossRef
227.
Chia R, Chiò A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17(1):94–102.PubMedCrossRef
228.
Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18(2):211–20.PubMedCrossRef
229.
Morrice JR, Gregory-Evans CY, Shaw CA. Animal models of amyotrophic lateral sclerosis: a comparison of model validity. Neural Regen Res. 2018;13(12):2050–4.PubMedPubMedCentralCrossRef
230.
Jin M, Günther R, Akgün K, Hermann A, Ziemssen T. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Sci Rep. 2020;10(1):5941.PubMedPubMedCentralCrossRefADS
231.
Garofalo S, Cocozza G, Porzia A, Inghilleri M, Raspa M, Scavizzi F, et al. Natural killer cells modulate motor neuron-immune cell cross talk in models of Amyotrophic Lateral Sclerosis. Nat Commun. 2020;11(1):1773.PubMedPubMedCentralCrossRefADS
232.
Murdock BJ, Famie JP, Piecuch CE, Raue KD, Mendelson FE, Pieroni CH, et al. NK cells associate with ALS in a sex- and age-dependent manner. JCI Insight. 2021;6(11).
233.
Rolfes L, Schulte-Mecklenbeck A, Schreiber S, Vielhaber S, Herty M, Marten A, et al. Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation. Brain Commun. 2021;3(3):fcab157.PubMedPubMedCentralCrossRef
234.
Gong Z, Liu Y, Ding F, Ba L, Zhang M. Natural killer cells-related immune traits and amyotrophic lateral sclerosis: a Mendelian randomization study. Front Neurosci. 2022;16.
235.
Komine O, Yamashita H, Fujimori-Tonou N, Koike M, Jin S, Moriwaki Y, et al. Innate immune adaptor TRIF deficiency accelerates disease progression of ALS mice with accumulation of aberrantly activated astrocytes. Cell Death Differ. 2018;25(12):2130–46.PubMedPubMedCentralCrossRef
236.
Xu X, Shen D, Gao Y, Zhou Q, Ni Y, Meng H, et al. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed? Transl Neurodegener. 2021;10(1):29.PubMedPubMedCentralCrossRef
237.
Mead RJ, Shan N, Reiser HJ, Marshall F, Shaw PJ. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discovery. 2023;22(3):185–212.PubMedCrossRef
238.
Nikitin D, Makam AN, Suh K, McKenna A, Carlson JJ, Richardson M, et al. The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: a summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council. J Manag Care Spec Pharm. 2023;29(2):216–21.PubMed
239.
Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, Al-Chalabi A. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17(5):416–22.PubMedPubMedCentralCrossRef
240.
Figueroa-Romero C, Monteagudo A, Murdock BJ, Famie JP, Webber-Davis IF, Piecuch CE, et al. Tofacitinib suppresses natural killer cells in vitro and in vivo: implications for amyotrophic lateral sclerosis. Front Immunol. 2022;13.
241.
Shimaoka H, Takeno S, Maki K, Sasaki T, Hasegawa S, Yamashita Y. A cytokine signal inhibitor for rheumatoid arthritis enhances cancer metastasis via depletion of NK cells in an experimental lung metastasis mouse model of colon cancer. Oncol Lett. 2017;14(3):3019–27.PubMedPubMedCentralCrossRef
Metadata
Title
The role of CD56bright NK cells in neurodegenerative disorders
Authors
Carla Rodriguez-Mogeda
Chaja M. J. van Ansenwoude
Lennart van der Molen
Eva M. M. Strijbis
Reina E. Mebius
Helga E. de Vries
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2024
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/s12974-024-03040-8

Other articles of this Issue 1/2024

Journal of Neuroinflammation 1/2024 Go to the issue

Review

Taming microglia: the promise of engineered microglia in treating neurological diseases

Research

Hypochlorous acid derived from microglial myeloperoxidase could mediate high-mobility group box 1 release from neurons to amplify brain damage in cerebral ischemia–reperfusion injury

Research

Enhanced meningeal lymphatic drainage ameliorates lipopolysaccharide-induced brain injury in aged mice

Research

Inhibition of MMP8 effectively alleviates manic-like behavior and reduces neuroinflammation by modulating astrocytic CEBPD

Research

Bone-derived PDGF-BB enhances hippocampal non-specific transcytosis through microglia-endothelial crosstalk in HFD-induced metabolic syndrome

Review

Mitochondrial and metabolic dysfunction of peripheral immune cells in multiple sclerosis